In addition, role of MCL-1 in selecting patients whose tumor is more likely to respond to these CDK9 inhibitors with or without chemotherapy and radiation need to be studied in esophageal adenocarcinoma. The gene discussed is CDK9; the disease is esophageal adenocarcinoma.